|
![]() |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name MEDIFRON DBT CO.,LTD. Headquarters RM.1401,A-DONG,WOORIM BLUE NINE BUSINESS CENTER,24, 0-21, YEOMCHANG-DONG, GANGSEO-GU, SEOUL; Seoul; Seoul; 157861 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: SINHAN (2011) Incorporation Date: March 18, 1997 Total Employees: 25 Tel: 02-545-9277 |
|
Company Description |
| Despite sluggish contents biz, firms sales rose YoY, because of favorable tune in IT distribution sector including monitors, and new sales of new drugs including pain killer.Net profit turned into surplus, in view of cost ratio decline including high margin goods sales, and elimination of loss on equity method related to Digital Biotech in the first half.The firm has R&D network equipped with global competitiveness, owing to technology transfer of neural pain treatment drug and dementia drug to Grudental | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues decreased with -22.73%, from KRW 6,107,707 thousands to KRW 4,719,174 thousands. Operating Results decreased from KRW 170,418 thousands to KRW -1,447,583 thousands. The results of the period reached KRW -1,452,892 thousands at the end of the period against KRW 176,718 thousands last year. Return on equity (Net income/Total equity) went from 0.46% to -4.00%, the Return On Asset (Net income / Total Asset) went from 0.43% to -3.89% and the Net Profit Margin (Net Income/Net Sales) went from 2.89% to -30.79% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 2.69% compared to 7.68% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 4.63 to 32.94 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |

|
|
2012 H1 (non-cons) |
2011 Y (non-cons) |
|
![]() | ||
| Audited | Audited | |
![]() | ||
| KR listed company financials | KR listed company financials | |
![]() | ||
| Unit | Thousands | Thousands |
![]() | ||
![]() | ||
Total Assets |
37,325,001 |
38,643,828 |
![]() | ||
Current Assets |
9,426,090 |
10,706,101 |
![]() | ||
Total Liabilities |
977,110 |
843,044 |
![]() | ||
Shareholders Equity |
36,347,892 |
37,800,784 |
![]() | ||
Current Liabilities |
286,168 |
423,012 |
![]() | ||
| * All the accounts are in KRW. | ||
![]() | ||
Total Operating Revenue |
4,719,174 |
13,231,774 |
![]() | ||
Operational Profit (Loss) |
-1,447,583 |
681,143 |
![]() | ||
Net Profit (Loss) |
-1,452,892 |
684,158 |
![]() | ||
| * All the accounts are in KRW. | ||
| Profitability Ratios | ||
![]() | ||
Return on Assets (ROA) |
-3.89% |
1.77% |
![]() | ||
Return on Equity (ROE) |
-4% |
1.81% |
![]() | ||
Return on Sales (ROS) |
-30.79% |
5.17% |
![]() | ||
Return on Capital |
-3.92% |
1.79% |
![]() | ||
Gross Profit Margin |
-7.78% |
19.12% |
| Efficiency Ratios | ||
![]() | ||
Current asset turnover |
0.50x |
1.24x |
![]() | ||
Asset Turnover |
0.13x |
0.34x |
| Valuation figures and ratios | ||
![]() | ||
Earning Before Interests and Taxes (EBIT) |
-1,452,892 |
452,676 |
![]() | ||
EBITDA |
-1,436,065 |
704,144 |
![]() | ||
Bookvalue (BV) |
8,785,135 |
10,241,808 |
| Liquidity Ratios | ||
![]() | ||
Current Ratio |
3,293.9% |
2,530.92% |
![]() | ||
Quick ratio |
2,565.19% |
1,838.51% |
![]() | ||
Doom's day ratio |
859.88% |
693.91% |
![]() | ||
Cash Flow to Debt |
-48.57% |
-14.66% |
| Leverage Ratios | ||
![]() | ||
Leverage ratio |
102.69% |
102.23% |
![]() | ||
Interest Coverage Ratio |
0% |
397.64% |
![]() | ||
Debt to equity |
2.69% |
2.23% |
![]() | ||
Debt to total assets |
2.62% |
2.18% |
![]() | ||
Long Term Debt to Capital |
1.87% |
1.1% |
| Market ratios | ||
![]() | ||
Price/Book Ratio |
4.29 |
5.38 |
| Trend Ratios | ||
![]() | ||
Revenue Trend |
77.27% |
107.95% |
![]() | ||
Net Income Trend |
-822.15% |
-28.48% |
![]() | ||